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Insulin and insulin-like growth factor-1 (IGF-1) have
similar cell-surface receptors yet subserve different
physiological functions. To examine whether these dif-
ferences relate to intrinsic signaling properties of the
intracellular domains of their respective receptors, chi-
meric receptors were constructed using the extracellu-
lar domain of the neurotrophin-3 (NT-3) receptor, TrkC,
and the intracellular domain of either the insulin recep-
tor or the IGF-1 receptor. TrkC-IR (TIR) and TrkC-
IGF-1R (TIGR) were stably expressed in 3T3-L1 cells.
While TIR and TIGR cell lines expressing similar num-
bers of chimeric receptors showed a similar dose-re-
sponse relationship in NT-3 stimulated DNA synthesis,
NT-3 stimulated glycogen synthesis was greater in TIR
than in TIGR cells (maximum TIGR response was 35% of
maximum TIR response). Additionally, the concentra-
tion of NT-3 at which significant stimulation of glycogen
synthesis was seen was 0.1 ng/ml in TIR and 1 ng/ml in
TIGR cells. Basal levels of thymidine incorporation but
not glycogen synthesis were consistently higher in TIR
than in TIGR expressing cells. No detectable basal auto-
phosphorylation of chimeric receptors was seen in any
of the cell lines. However, exposure of cell lines to the
phosphatase inhibitor bisperoxovanadate resulted in
greater basal autophosphorylation of the TIR and en-
dogenous murine IR than the TIGR and endogenous
murine IGF-1R. Thus, in this system, the intracellular
domain of the IR appears to couple more effectively to
glycogen synthesis than that of the IGF-1R, whereas the
intracellular domains of both receptors have a similar
capacity to stimulate DNA synthesis.
Insulin and insulin-like growth factor-1 (IGF-1)1 are homol-
ogous peptides that are essential for normal metabolism and
growth regulation. In the intact organism these hormones have
significantly different physiological roles (for review, see Refs.
1–3). Insulin primarily functions as a regulator of carbohy-
drate, fat, and protein metabolism. In contrast, IGF-1 is largely
a mediator of cell growth and differentiation primarily stimu-
lating DNA synthesis and mitogenic events (4–6). Despite
these different functions, the cell surface receptors for insulin
and IGF-1 (IR and IGF-1R, respectively) are highly homolo-
gous. They are both Type II tyrosine kinase receptors with the
same disulfide-linked heterotetrameric structure consisting of
two extracellular a-subunits containing the ligand-binding do-
main and two transmembrane b-subunits with the ligand-sen-
sitive tyrosine kinase activity (7). The greatest homology (over
80%) is found in the tyrosine kinase domain while differences
in the ligand-binding domain (overall homology 44–60%) ac-
count for ligand specificity. The greatest sequence divergence
between the two receptors is found in their C termini (44%
identity) (8).
In addition to the similarity of receptor structure the intra-
cellular signaling events which result from ligand-induced re-
ceptor activation are remarkably similar (9). Both receptors
phosphorylate insulin-receptor substrates IRS-1 (10–13),
IRS-2 (14, 15), and Shc (16, 17) on tyrosine residues with the
subsequent activation of a wide range of signaling molecules
including those of the Ras-Raf-MAP kinase network (18–21)
and phosphatidylinositol 3-kinase (22–24). It is widely as-
sumed that the IR transduces a metabolic signal and the IGF-1
receptor a mitogenic one. However, it has been shown that both
receptors are able to transduce both mitogenic and metabolic
signals. IGF-1 has been shown to regulate glycogen metabolism
in human hepatoma cells (25) and glucose transport in muscle
(26) via the IGF-1R, while insulin can stimulate cell growth
through its receptor in human fibroblasts (27) and Chinese
hamster ovary (CHO) cells (28). Insulin has also been found to
transduce a mitogenic signal through its own receptor when
overexpressed in NIH 3T3 or CHO cells (29–31).
Both in vitro and ex vivo approaches have been taken to
examine the issue of signaling specificity of the IR versus the
IGF-1R. The former studies have examined the catalytic activ-
ity of semipurified IRs versus IGF-1Rs toward different peptide
substrates and have suggested that consistent differences may
exist (32, 33). Ex vivo approaches have either compared meta-
bolic versus mitogenic effects in cell lines overexpressing the IR
versus those overexpressing the IGF-1R (34–37) or have stud-
ied the signaling properties of chimeric receptors composed of
parts of the IR and IGF-1R (38–40).
Issues such as cross-reactivity of the ligands for their non-
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cognate receptor and the formation of hybrid receptors may
have complicated interpretation of previous studies. To over-
come some of the inherent limitations in previous systems,
we have constructed chimeric receptors using the extracellu-
lar and most of the transmembrane domain of the neurotro-
phin-3 (NT-3) receptor TrkC (a monomeric transmembrane
receptor tyrosine kinase) and the intracellular domain of
either the IR or IGF-1R. As TrkC is known to be activated by
ligand-induced dimerization, it was anticipated that the mo-
nomeric chimera would be inactive in the absence of ligand.
Neither TrkC nor NT-3 are expressed in 3T3-L1 pre-adipo-
cytes, nor is there any biological response to NT-3 in these
cells. Thus these chimeras have allowed us to examine the
relative abilities of the intracellular domains of the IR and
IGF-1R to stimulate glycogen versus DNA synthesis in
3T3-L1 pre-adipocytes in response to comparable degrees of
receptor activation by a single ligand.
EXPERIMENTAL PROCEDURES
Materials—Anti-IR and anti-IGF-1R antibodies were polyclonal an-
tibodies raised to the C-terminal region of the IR and IGF-1R, respec-
tively. Polyclonal anti-Trk C-terminal peptide antibody was as de-
scribed (41). Anti-phosphotyrosine antibody 4G10 was purchased from
Upstate Biotechnology Inc. (Bucks., United Kingdom). Unless other-
wise stated, all biochemicals and cell culture materials were from
Sigma (Poole, Dorset, UK) and general purpose laboratory reagents
were of analytical grade and obtained from BDH (Poole, Dorset, UK).
D-[14C]Glucose, [methyl-3H]thymidine, and Na125I were from
Amersham (Ayelsbury, Buckinghamshire, UK).
Cell Culture—Parental 3T3-L1 pre-adipocytes (American Type Cul-
ture Collection) were maintained in Dulbecco’s modified Eagle’s me-
dium supplemented with 10% (v/v) newborn calf serum, 50 units/ml
penicillin/streptomycin, and 2 mM glutamine. Stably transfected
3T3-L1 pre-adipocytes were maintained in the same medium contain-
ing 550 mg/ml G418 (Life Technologies, Inc.). CHO.IR cells are stably
transfected CHO cells overexpressing the wild-type insulin receptor
(42). These were maintained in F-12 medium supplemented with 10%
fetal calf serum, 50 units/ml penicillin/streptomycin, 2 mM glutamine,
and 600 mg/ml G418. MG86/TrkC cells are stably transfected NIH 3T3
cells overexpressing the TrkC cDNA (43). These were maintained in
Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bo-
vine serum (Sigma C-5155), 50 units/ml penicillin/streptomycin, 2 mM
glutamine, and 500 mg/ml G418. 3T3/IGF-1R are stably transfected
NIH 3T3 cells overexpressing the IGF-1R (44). These were maintained
in the same medium as wild-type 3T3-L1 pre-adipocytes.
Generation of Chimeric Receptors—Site-directed mutagenesis was
used to introduce novel restriction sites in the transmembrane domain
of the IR, IGF-1R, and TrkC. Mutants were generated using “Altered
Sites II in vitro Mutagenesis System” (Promega). A DraI site was
introduced into the TrkC cDNA using a mutagenic oligonucleotide
corresponding to nucleotides 2426–2451 (59-CTTGTTGATCATTTTA-
AAGAGGACCA-39; the DraI site is underlined and the mutated nucle-
otides are boldfaced). A SnaBI site was introduced into the IR cDNA
using a mutagenic oligonucleotide corresponding to nucleotides 2921–
2954 (59-TTGGAAGTATTTACGTATTCCTGAGAAA-39; the SnaBI site
is underlined and the mutated oligonucleotides are boldfaced). A SnaBI
site was introduced into the IGF-1R cDNA using a mutagenic oligonu-
cleotide corresponding to nucleotides 2906–2926 (59-TTCTATGGAAT-
ACGTACAGCA-39; the SnaBI site is underlined and the mutated nu-
cleotide is boldfaced). The DraI site does not alter any amino acids in
the region of TrkC to be used in the chimeric receptor. The SnaBI sites
produce a conservative L938V change in the IR and no change in the
IGF-1R. TrkC was then cleaved with DraI and the IR and IGF-1R with
SnaBI followed by blunt-end ligation of the TrkC extracellular domain
to the intracellular domain of either the IR or the IGF-1R producing the
TIR and TIGR, respectively. The sequences of the transmembrane
domains of the wild-type receptors are: IR, IIIGPLIFVFLFSVVIG-
SIYLFL; IGF-IR, LIIALPVAVLLIVGGLVIMLYVHF; and TrkC, FGV-
SIAVGLAAFACVLLVVLFIMI. The sequences of the transmembrane
domains of the chimeric receptors are: TIR, FGVSIAVGLAAFACVLLV-
VLFVFL and TIGR, FGVSIAVGLAAFACVLLVVLFVHF, where the
boldfaced residues are derived from the IR and IGF-IR, respectively,
and the underlined residue represents the conservative L938V change
in the IR. The chimeric receptors were subcloned into pRc/CMV (In-
vitrogen, Leek, Norway) for expression in 3T3-L1 pre-adipocytes from
the cytomegalovirus promoter. The entire transmembrane domain and
300 flanking nucleotides of both chimeras were sequenced in the final
vector.
Generation of Stable Cell Lines—Semi-confluent 3T3-LI pre-adipo-
cytes in 6-well dishes were transfected with 1.5 mg of either pRc/CMV/
TIR or pRc/CMV/TIGR using 8 ml of the Lipofectamine reagent (Life
Technologies, Inc., Paisley, Scotland) according to the manufacturer’s
protocol. Three days after transfection, selective media containing 550
mg/ml G418 was added. After 3 weeks of G418 selection, clonal lines
were obtained by limiting dilution onto 96-well plates.
Labeling and Binding of [125I]NT-3—G418-resistant clones express-
ing high levels of transfected receptor were selected by measurement of
[125I]NT-3 binding. NT-3 was labeled according to the following protocol
from Regeneron Pharmaceuticals: 4 mg of NT-3 were mixed with 0.5 mg
of lactoperoxidase, 400 mCi of Na125I (2000 Ci/mmol), and H2O2 at a
final concentration of 176 mM. All dilutions were done in 0.2 M sodium
phosphate buffer, pH 6.0. After 12 min (vortexing vigorously after 6
min), the reaction was terminated by addition of 30 ml of CIP buffer (0.1
M sodium phosphate, 1 M NaCl, 0.1 M NaI, pH 7.5). The entire volume
was then transferred to a BSA-coated Eppendorf tube and the reaction
vial flushed with a further 40 ml of 1–2% BSA (radioimmunoassay
grade). Half of the total volume was diluted to 100 ml and spun through
a Sephadex G-25 spin column to remove unincorporated label. Labeled
NT-3 was found to have a specific activity of 2000–3000 cpm/fmol.
[125I]NT-3 was stored at 4 °C and used within 2 weeks of preparation.
All binding studies were performed overnight at 4 °C with shaking,
using confluent 24-well plates with a total volume of 300 ml/well. For
selection of high-expressing clones, cells were incubated with 24 pM
[125I]NT-3, washed with ice-cold PBS and solubilized in 0.03% SDS. The
radioactivity was measured in a NE1660 g-counter. Nonspecific binding
was determined by preincubating the cells for 45 min with a 1000-fold
excess of cold NT-3. It was found to account for maximally 10–20% of
total binding. For displacement experiments, cells were incubated with
12 pM [125I]NT-3 and unlabeled NT-3 at concentrations between 0 and
600 pM.
Immunoprecipitation—Confluent 4-well plates were incubated in se-
rum-free media overnight followed by addition of ligand (insulin, IGF-1,
or NT-3) for 5 min. In experiments using bisperoxovanadium phenan-
throline (bpV(phen)), the cells were exposed to bpV(phen) for 10 min
followed by 5 min with or without ligand. Cells were then washed once
with ice-cold PBS, solubilized in 0.5 ml of lysis buffer (50 mM Hepes, 150
mM NaCl, 1% Triton X-100, 1 mM Na3VO4, 10 mM Na4P2O7, 30 mM
sodium fluoride, 30 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 2.5
mM benzamidine, 1 mg/ml antipain, 1 mg/ml leupeptin, and 1 mg/ml
pepstatin) and clarified by centrifugation. Supernatants were incu-
bated for 4 h at 4 °C with 2 ml of either anti-IR or anti-IGF-1R antibody
or 5 ml of anti-TrkC antibody plus 40 ml of a 5% slurry of protein
A-agarose. After four washes with lysis buffer, pellets were resus-
pended in Laemmli sample buffer containing 100 mM dithiothreitol and
boiled for 3 min. For analysis of total cell lysates, aliquots of lysate
supernatant were mixed with sample buffer containing dithiothreitol.
Western Blotting—Proteins were resolved by SDS-polyacrylamide gel
electrophoresis (7.5% slab gels) and transferred by electroblotting onto
polyvinylidene difluoride membrane (Millipore Corp., Bedford, MA).
The membrane was incubated in blocking buffer (PBS, 0.1% Tween 20,
3% BSA) for 1 h at room temperature. Blocking was followed by incu-
bation at room temperature for 1 h with either anti-IR, anti-IGF-IR, or
anti-phosphotyrosine antibody 4G10 in PBS, 0.1% Tween 20, 0.5% BSA.
The membrane was then washed for 30 min: 3 3 5 min with PBS, 0.1%
Tween and 3 3 5 min with water. Washing was followed by incubation
with secondary antibody for 1 h at room temperature. This was followed
by another 30-min wash as described above. For detection by the ECL
system (Amersham, Ayelsbury, Bucks., UK), the secondary antibody
was horseradish peroxidase-conjugated anti-mouse (or anti-rabbit) IgG
(Dako Ltd., Denmark) diluted 1:10000 in PBS, 0.1% Tween 20, 0.5%
BSA. For detection using 125I, approximately 1 mCi of 125I-labeled goat
anti-mouse (or anti-rabbit) IgG (gift of Paul Bevan, Cambridge, UK)
was used as secondary antibody. The washed filter was then exposed to
x-ray film with an intensifier screen or exposed to a PhosphorImager
plate. The results were viewed and quantified using a Fuji BAS2000
PhosphorImager.
Glycogen Synthesis Assay—Glycogen synthesis was assessed by
measuring D-[14C]glucose incorporation into glycogen. Confluent mono-
layers in 6-well dishes were serum-starved for 18 h followed by addition
of either 0.001–10 ng/ml NT-3 or 100 nM insulin for 30 min and meas-
urement of D-[14C]glucose uptake as described (45). The unlabeled glu-
cose concentration was 5 mM.
Thymidine Incorporation Assay—Confluent monolayers in 24-well
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dishes were serum-starved for 24 h in serum-free media. Cells were
then washed in serum-free media followed by the addition of either 1 mM
insulin or 0.001–1 mg/ml NT-3. After 22 h, thymidine incorporation was
measured as described (46).
RESULTS
Design of Chimeric Receptors—To select an appropriate ex-
tracellular chimeric partner for these studies a number of
ligands were examined to ensure they did not activate down-
stream signaling in 3T3-L1 pre-adipocytes. Both NGF and
HGF were found to produce biological responses in 3T3-L1
pre-adipocytes. In contrast, NT-3 did not stimulate glycogen
synthesis or thymidine incorporation in 3T3-L1 pre-adipocytes
(Fig. 1, A and B), while these processes responded to insulin
and serum, respectively. Conditioned medium was harvested
from 3T3-L1 pre-adipocytes and assayed for the presence of
ligand that could activate TrkC in MG86/TrkC cells. There was
no increase in TrkC phosphorylation in cells exposed to the
supernatants suggesting these cells do not express NT-3 (Fig.
1C). Therefore, TrkC was chosen as the receptor to be used in
the construction of the chimeric receptors.
Expression and Autophosphorylation of Chimeric Recep-
tors—Chimeric receptors consisting of the entire extracellular
domain and 21 amino acids of the transmembrane domain of
TrkC and the intracellular domain of the insulin or IGF-1
receptor (TIR and TIGR, respectively) were cloned into the
mammalian expression vector pRc/CMV which also contains an
SV40 promoter-driven G418 resistance gene. The resulting TIR
and TIGR expression vectors were transfected into 3T3-L1
pre-adipocytes followed by growth in G418 to generate a pool of
stably transfected cells. To determine whether the chimeric
receptors were correctly synthesized and expressed, total cell
lysates from these pools were analyzed by 7.5% SDS-PAGE,
followed by anti-IR or anti-IGF-1R blotting of proteins trans-
ferred to polyvinylidene difluoride membrane (Fig. 2). Both
chimeric receptors were expressed and migrated on SDS-PAGE
with an apparent molecular mass of 145–150 kDa. Neither
receptor was expressed in parental 3T3-L1 cells while all cell
lines expressed the IR and IGF-1R.
We examined the functionality of the chimeric receptors in
the pools of stably transfected 3T3-L1 stimulated with NT-3. In
the absence of suitable antibody to immunoprecipatate chi-
meric receptors via TrkC extracellular domain, receptors were
immunoprecipitated with antibodies to the intracellular do-
main of the IR or IGF-1R then immunoblotted with an anti-
phosphotyrosine antibody (Fig. 3). The anti-IR and anti-
IGF-1R antibodies both recognized the respective endogenous
murine receptors but they could be clearly distinguished from
the chimeric receptor because of major size differences. Both
the TIR and TIGR showed NT-3-dependent autophosphoryla-
tion of the chimeric receptor but not of the endogenous insulin
or IGF-1 receptor. NT-3 also stimulated autophosphorylation of
TrkC in MG86/TrkC cells while insulin and IGF-1 stimulated
autophosphorylation of their cognate receptor in CHO.IR and
3T3/IGF-1R cells, respectively.
Ligand Binding—Limiting dilution of the 3T3-L1 pool was
used to generate several independent G418-resistant clonal cell
lines expressing the TIR or TIGR. [125I]NT-3 binding was used
to select clones expressing high levels of chimeric receptor and
FIG. 3. NT-3 stimulated tyrosine phosphorylation of chimeric
receptors in pools of stably transfected cells. 1, 3T3/IGF-1R; 2,
3T3-L1/TIGR pool; 3, CHO.IR; 4, 3T3-L1/TIGR pool; 5, MG86/TrkC.
Confluent 4-well dishes were serum-starved overnight, then treated
with or without ligand (50 ng/ml NT-3, 100 nM insulin, or 10 nM IGF-1)
for 5 min. Cells were harvested, receptor immunoprecipitated with
anti-IR, anti-IGF-1R, or anti-TrkC antibody, followed by SDS-PAGE
and immunoblotting with anti-phosphotyrosine antibody 4G10 and de-
tection by ECL.
FIG. 1. A, stimulation of glycogen synthesis in 3T3-L1 pre-adipocytes.
Cells were stimulated with 100 nM insulin or 50 ng/ml NT-3. B, stim-
ulation of thymidine incorporation in 3T3-L1 pre-adipocytes. Cells were
stimulated with serum or 50 ng/ml NT-3. All assays were carried out in
triplicate. Results are the mean 6 S.D. of three independent experi-
ments and are expressed as fold over basal. C, phosphorylation of TrkC
by NT-3. Fcd, fibroblast control media not exposed to cells; FM, fibro-
blast conditioned media. Cells were serum-starved for 2 h, treated with
media 6 NT-3 for 5 min, extracted, TrkC immunoprecipitated with
anti-TrkC antibody, and blotted with anti-phosphotyrosine antibody
4G10.
FIG. 2. Expression of chimeric receptors in pools of stably
transfected cells. 1, 3T3/TIGR pool; 2 and 6, untransfected 3T3-L1; 3,
3T3/IGF-1R; 4, CHO.IR; 5, 3T3-L1/TIR pool. Confluent 4-well plates
were harvested and total cell lysates analyzed by SDS-PAGE followed
by immunoblotting with anti-IR or anti-IGF-1R antibodies and detec-
tion by the ECL system.
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to identify pairs of clones expressing similar levels of TIR and
TIGR. Each pair was analyzed in triplicate on at least two
different occasions with MG86/TrkC cells and parental 3T3-L1
pre-adipocytes as positive and negative controls, respectively.
Two pairs of clones were selected for use in further studies:
TIGR1/TIR1 and TIGR2/TIR2 where both clones of each pair
bound similar amounts of [125I]NT-3 (data not shown). The
displacement of [125I]NT-3 tracer by unlabeled NT-3 was com-
parable in the pairs of TIR versus TIGR clones (Fig. 4).
Response of Paired Clones to NT-3—We then examined the
dose-response of NT-3-induced chimera autophosphorylation in
the paired clones. Serum-starved cells were incubated for 5 min
with 0.1–1000 ng/ml NT-3 followed by immunoprecipitation
with anti-IR or anti-IGF-1R antibody and immunoblotting with
anti-phosphotyrosine antibody 4G10 (Fig. 5). Paired clones
showed a similar dose-response to NT-3 reaching a maximum
at 100 ng/ml. Chimera autophosphorylation was reduced at the
higher NT-3 concentration of 1000 ng/ml, a finding consistent
with the known properties of transmembrane receptors which
FIG. 4. Displacement of bound [125I]NT-3 by cold NT-3 in clones
expressing either the TIGR or TIR. Cells were incubated overnight
at 4 °C with 12 pM [125I]NT-3 and unlabeled NT-3 at concentrations
between 0 and 600 pM, washed with ice-cold PBS, and solubilized in
0.03% SDS. The radioactivity was measured in a NE1660 g-counter.
FIG. 5. Dose-response of tyrosine phosphorylation in paired
3T3-L1/TIR and 3T3-L1/TIGR cell lines. Confluent 4-well dishes
were serum-starved overnight then exposed to 0–1000 ng/ml NT-3 for 5
min. Cells were harvested, receptor immunoprecipitated with anti-IR or
anti-IGF-1R antibody, followed by SDS-PAGE and immunoblotting
with anti-phosphotyrosine antibody 4G10. Tyrosine-phosphorylated re-
ceptor was detected using 1 mCi of 125I-labeled goat anti-mouse IgG as
secondary antibody.
FIG. 6. Stimulation of glycogen synthesis. Confluent 6-well
dishes were serum-starved overnight followed by addition of 1 pg/ml to
10 ng/ml NT-3 (or 100 nM insulin) for 30 min and D-[14C]glucose for
1.5 h. A, stimulation of glycogen synthesis in TIGR1 and TIR1. E,
TIGR1; l, TIR1; 3, parental 3T3-L1 pre-adipocytes (3T3). B, stimula-
tion of glycogen synthesis in TIGR2 and TIR2. M, TIGR2 cells; f, TIR2
cells; and 3, parental 3T3-L1 pre-adipocytes (3T3). C, all cell lines
showed a similar response to 100 nM insulin. 3T3-L1 is expressed as %
maximum TIR2. Results are presented as % maximum TIR response
calculated as: (dpm-basal)/(maximum dpm of TIR clone-basal) 3 100.
Basal levels of D-[14C]glucose incorporation were comparable for TIGR
clones, TIR clones, and 3T3-L1 pre-adipocytes at approximately 3.3
pmol of [14C]glucose incorporated per 106 cells/h). Typically, maximum
NT-3 stimulation for TIR clones was 7.4 pmol of [14C]glucose incorpo-
rated per 106 cells/h while maximum insulin stimulation for TIR clones
was typically 9 pmol of [14C]glucose incorporated per 106 cells/h. Results
are mean 6 S.E. of three independent experiments performed in dupli-
cate. *, p , 0.02; **, p , 0.01; ***, p , 0.005 using the nonparametric
Mann-Whitney test.
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are dimerized by ligand (47, 48).
Biological Activity and Specificity of Chimeric Receptors—
The paired clones TIGR1/TIR1 and TIGR2/TIR2 were then
used to compare the effect of NT-3 on glycogen synthesis in
cells (Fig. 6). Serum-starved cells were exposed to various
concentrations of NT-3 for 30 min followed by a 1.5-h pulse of
D-[U-14C]glucose. Results are shown separately for each of the
matched pairs and represent the mean results from three in-
dependent experiments. Parental 3T3-L1 cells did not respond
to NT-3 but glycogen synthesis was stimulated by NT-3 in both
pairs of chimeric expressing cell lines. The dose-response
curves show that, in both pairs, NT-3 stimulated glycogen
synthesis was greater in TIR than in TIGR expressing clones.
The maximal response seen in both TIR1 and TIR2 was almost
3 times that of TIGR1 and TIGR2, respectively. Additionally,
the concentration at which significant stimulation of glycogen
synthesis was seen was 10-fold higher in TIGR1 and TIGR2
than in TIR1 and TIR2 (1 versus 0.1 ng/ml). All clones showed
a similar response to 100 nM insulin suggesting that the differ-
ences seen are specific to NT-3.
The effect of NT-3 on thymidine incorporation in TIGR1/
TIR1 and TIGR2/TIR2 was also examined. Serum-starved cells
were exposed to various concentrations of NT-3 for 22 h fol-
lowed by a 1.5-h pulse of [methyl-3H]thymidine. Parental
3T3-L1 cells did not respond to NT-3 but [3H]thymidine incor-
poration was stimulated by NT-3 in both pairs of chimeric
expressing cell lines (Fig. 7). In contrast to the studies of
glycogen synthesis, the dose-response characteristics of DNA
synthesis were comparable in both pairs of TIR versus TIGR
expressing clones. All clones showed a similar response to 1 mM
insulin.
Receptor Autophosphorylation in the Presence of BpV-
(phen)—While the NT-3 dose-response of thymidine incorpora-
tion was very similar in TIR and TIGR expressing clones, a
consistent increase in basal levels of thymidine incorporation
(but not glycogen synthesis) was seen in the TIR versus TIGR
expressing clones. The basal levels of thymidine incorporation
in TIGR clones were around 4000 dpm (approximately 2% of
maximal NT-3 response), whereas in TIR clones the basal
levels of thymidine incorporation were around 20,000 dpm
(approximately 10% of maximal NT-3 response).
These differences in basal levels of thymidine incorporation
were not associated with parallel differences in cell prolifera-
tion as the doubling times of all cell lines was similar (data not
shown). The differences on basal levels of thymidine incorpo-
ration could not be explained by a greater degree of basal
receptor autophosphorylation of the TIR as none could be de-
tected in any of the clonal cell lines studied. However, it was
possible that a small amount of such basal activity might have
been undetectable by immunoblotting.
To amplify basal autophosphorylation, cells were exposed to
the phosphatase inhibitor bpV(phen) prior to addition of ligand
(Fig. 8). In the absence of ligand and bpV(phen) (lanes 1 and 6)
there is no detectable basal autophosphorylation of either the
chimeric or endogenous receptors. When NT-3 is added, there
is stimulation of autophosphorylation of the TIGR (lane 2) and
the TIR (lane 7). In the presence of bpV(phen) and absence of
NT-3, the extent of basal chimeric receptor autophosphoryla-
tion of the TIR was greater than that of the TIGR (comparing
TIR in lanes 8 and 10 with TIGR in lanes 3 and 5).
This raised the possibility that the structural alteration of
the TIR chimera might have resulted in a degree of “artificial”
constitutive activation which did not occur to a similar extent
with the TIGR chimera. However, in the presence of bpV(phen)
alone, the endogenous murine IR showed a comparable hyper-
sensitivity to bpV(phen) compared with the endogenous murine
IGF-1R (IGF-IR in lane 3). This indicates that these findings
are more likely to relate to intrinsic differences in the proper-
ties of the IR versus IGF-1R intracellular domains rather than
FIG. 7. Stimulation of thymidine incorporation. Confluent 24-
well plates were serum-starved for 24 h. Cells were then washed in
serum-free media followed by the addition of either 1 mM insulin or
0.001–1 mg/ml NT-3. After 22 h, 1 mCi of [methyl-3H]thymidine was
added to each well for 1.5 h. A, stimulation of thymidine incorporation
in TIGR1 and TIR1. E, TIGR1; l, TIR1; 3, parental 3T3-L1 pre-
adipocytes (3T3). B, stimulation of thymidine incorporation in TIGR2
and TIR2. M, TIGR2 cells; f, TIR2 cells; and 3, parental 3T3-L1
pre-adipocytes (3T3). Basal levels of thymidine incorporation were ap-
proximately 3000–4000 dpm for 3T3-L1 pre-adipocytes, 4000 dpm for
TIGR clones (approximately 2% of maximal TIGR response), and 20,000
dpm for TIR clones (approximately 10% of maximal TIR response). C,
all clones showed a similar response to 1 mM insulin. 3T3-L1 is ex-
pressed as % maximum TIR2. Results are presented as % maximum
TIR incorporation calculated as: (dpm-basal)/(maximum dpm of TIR-
basal) 3 100. Results are mean 6 S.E. of four independent experiments
performed in duplicate.
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merely representing accidental properties of artificial chimeric
receptors. NT-3 is still able to stimulate autophosphorylation of
the TIGR and TIR in the presence of bpV(phen) (TIGR lane 4,
TIR lane 9) while IGF-I and insulin also stimulate autophos-
phorylation of their cognate receptor in the presence of bpV-
(phen) (IGF-IR lane 5, IR lane 10).
DISCUSSION
In the present study, we have found that the intracellular
domain of the IR is more active at stimulating glycogen syn-
thesis than that of the IGF-1R while both have a similar ca-
pacity to stimulate DNA synthesis. In the absence of ligand,
however, experiments with a phosphatase inhibitor suggest
that the IR has a higher level of basal kinase activity than the
IGF-1R. The fact that comparable results were obtained with
two independent pairs of clones provides reassurance that the
differences seen are likely to be biologically meaningful.
In the intact organism, these homologous peptide hormones
have very different functions. Insulin acts largely as a regula-
tor of metabolic processes while IGF-1 is predominantly in-
volved in the control of cell growth and differentiation. At least
four possible explanations for this specificity are apparent.
1) In vivo differences in the properties of insulin and IGF-1
might result from the different tissue distribution of the IR and
IGF-1R. The fact that there are considerably more IRs than
IGF-1Rs on adult adipocytes and hepatocytes could explain the
greater metabolic effects of insulin on these tissues. However,
there are tissues, such as skeletal muscle (the major site of
whole body glucose disposal) which express both IRs and IGF-
1Rs to high levels. 2) Insulin secretion from pancreatic b-cells
increases rapidly in response to nutrients and acts immediately
on target tissues. In contrast, IGF-1 forms stable complexes
with specific binding proteins. Since insulin has a short plasma
half-life, the insulin receptor is exposed to rapidly changing
ligand concentrations in vivo whereas the effects of IGF-1 on its
receptor is likely to be more “tonic.” 3) The time course of
activation of the receptor kinase may differ because of differ-
ences in ligand-binding kinetics (43, 44). DeMeyts et al. (43)
have demonstrated that a higher dissociation rate of ligands
from the IR compared with the IGF-1R would result in tighter
binding of IGF-1 to its receptor resulting in receptor activation
for a longer time compared with insulin and its receptor.
4) There could be differences in the intrinsic signaling proper-
ties of the receptor kinases. There have been several ap-
proaches used to investigate intrinsic signaling differences.
These have included in vitro studies of purified or partially-
purified receptors and studies of receptors overexpressed in cell
lines.
Using highly purified preparations of IGF-1R and IR, Sahal
et al. (31) demonstrated intrinsic differences in substrate spec-
ificity between the two kinases toward polymeric substrates.
Xu et al. (32) showed that the IR catalytic domain preferen-
tially phosphorylates peptides based on Tyr-987 and Tyr-727 of
IRS-1 while the IGF-1R preferentially phosphorylated a syn-
thetic peptide containing Tyr-895 of IRS-1, the Grb2-binding
site.
Several studies comparing cells overexpressing IRs or IGF-
1Rs have been reported. Lammers et al. (35) have demon-
strated that, while they stimulate glucose transport with sim-
ilar efficiency, when overexpressed in NIH 3T3 fibroblasts the
Km for IGF-1 stimulated DNA synthesis in IGF-1R overex-
pressing cells was an order of magnitude lower than that seen
with insulin in IR overexpressing cells. In studies of NIH 3T3
fibroblasts, Tartare et al. (36) reported that the maximum
stimulation of glycogen synthesis by insulin in IR overexpress-
ing cells was 2-fold greater than that of IGF-1 in IGF-1R
overexpressing cells. Additionally, in these studies, insulin was
reported to result in a 5-fold stimulation of p44mapk in IR
overexpressing cells, whereas IGF-1 only stimulated p44mapk
2.5-fold in IGF-1R overexpressing cells. Other studies have
examined the relative abilities of both receptors to act as tumor
promoter agents. Thus, Kaleko et al. (33) demonstrated that
overexpression of IGF-1R in NIH 3T3 cells as well as human
and rat fibroblasts resulted in IGF-1-induced transformation
and rapid tumor formation in nude mice. In contrast, overex-
pression of the IR in 3T3 cells while resulting in loss of contact
inhibition and focal growth, did not promote tumor formation
in nude mice (34).
A complementary approach has involved the study of chi-
meric receptors comprised of portions of the IR and IGF-R.
Lammers et al. (35) reported that a receptor consisting of the
ligand-binding domain of the IR and the cytoplasmic domain of
the IGF-1R is 10 times more active in stimulating DNA syn-
thesis than the IR itself in response to insulin. This is consist-
ent with their demonstration of a greater mitogenic signaling
capacity of the intact IGF-1R compared with the IR. Tartare et
al. (36) studied a chimeric IGF-1R in which the C-terminal 112
amino acids was replaced by the equivalent sequences of the
IR. This chimera behaved more like the intact IR than IGF-1R
in studies of glycogen synthesis and MAP kinase activation.
When studied in vitro together with partially-purified IRs and
IGF-1Rs (45), this chimera displayed an array of effects similar
to the IR rather than the IGF-1R.
Faria et al. (37) showed that substitution of the IR C termi-
nus with that of the IGF-1R resulted in an 80% decrease in
FIG. 8. Potentiation of autophosphorylation by bisperoxova-
nadium phenanthroline (bpV(phen)) in the TIGR1/TIR1 pair.
Confluent 4-well plates were incubated in serum-free media overnight
followed by incubation with or without 0.1 mM bpV(phen) for 10 min
then with or without ligand (100 ng/ml NT-3, 10 nM insulin, or 10 nM
IGF-1) for a further 5 min. Cells were harvested, receptor immunopre-
cipitated with anti-IR or anti-IGF-1R antibody, followed by SDS-PAGE
and immunoblotting with anti-phosphotyrosine antibody 4G10. Tyro-
sine-phosphorylated receptor was detected using 1 mCi of 125I-labeled
goat anti-mouse IgG as secondary antibody. A, the chimeric TIGR
receptor and the endogenous IGF-IR. 1, basal autophosphorylation in
the absence of ligands; 2, stimulation of TIGR autophosphorylation by
NT-3; 3, TIGR and IGF-IR in the presence of bpV(phen) and absence of
ligands showing potentiation of basal autophosphorylation; 4, stimula-
tion of TIGR autophosphorylation by NT-3 in the presence of bpV-
(phen); and 5, stimulation of IGF-IR autophosphorylation by IGF-I in
the presence of bpV(phen). B, the chimeric TIR receptor and the endog-
enous IR. Lane 6, basal autophosphorylation in the absence of ligands;
7, stimulation of TIR autophosphorylation by NT-3; 8, TIR and IR in the
presence of bpV(phen) and absence of ligands showing potentiation of
basal autophosphorylation; 9, stimulation of TIR autophosphorylation
by NT-3 in the presence of bpV(phen), and lane 10, stimulation of IR
autophosphorylation by insulin in the presence of bpV(phen). Similar
results were obtained with the TIGR2/TIR2 pair. All experiments were
performed on two separate occasions.
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c-fos mRNA induction and a significant reduction in thymidine
incorporation in response to insulin. In contrast, substitution of
the IGF-1R C-terminal with that of the IR did not affect ligand-
stimulated thymidine incorporation which was similar in NIH
3T3 cells overexpressing either the IR, IGF-1R, or the chimeric
receptor (30). These studies suggest that the C-terminal region,
poorly conserved between the two receptors, may be involved in
defining the specificity of downstream events.
The use of the TrkC-based chimeric receptor approach in our
studies has allowed the avoidance of several factors which may
have confounded previous approaches to the question. Thus,
1) NT-3 has no effects on untransfected 3T3-L1 cells. 2) Hybrid
formation between endogenous IR and IGF-1R receptors ap-
pears unlikely, particularly as no transphosphorylation of the
endogenous receptors was seen upon NT-3 treatment of the
chimera-expressing cells. 3) The use of the same extracellular
domain for both IR and IGF-1R-containing chimeras removes
any confounding effects of differences in ligand binding. The
similarities between the two chimeric receptors in terms of
displacement of labeled NT-3 by cold NT-3 and the similarities
in the dose-response characteristics of NT-3 stimulated chi-
mera autophosphorylation provides further reassurance in this
regard. Thus, it appears likely that the clear differences in the
coupling of the two chimeric receptors to ligand-induced glyco-
gen synthesis is most likely to represent intrinsic differences in
the signaling properties of the intracellular domains of the IR
versus the IGF-1R.
The finding of a modest but consistent increase in the basal
amount of radiolabeled thymidine incorporation in cells ex-
pressing the TIR versus TIGR chimera could not be explained
by detectable differences in the basal extent of chimera auto-
phosphorylation. However, when exposed to bpV(phen), TIR
autophosphorylation was greatly enhanced whereas only a
small effect on TIGR autophosphorylation was seen. This did
not appear to reflect artificial properties of the chimeras as the
same differential response to bpV(phen) was seen with the
endogenous murine IR and IGF-1R. It is therefore possible that
the intracellular domain of the insulin receptor exhibits a
greater degree of ligand independent autophosphorylation
than the equivalent domain of the IGF-1R. Alternatively, bpV-
(phen) may have some specificity for particular phosphatases
which preferentially act upon the IR. These findings are in
accordance with findings of marked enhancement of glucose
disposal when various animal models of NIDDM are treated
with vanadate or its derivatives (peroxovanadate).
Glycogen synthase is activated by net dephosphorylation
either by activation of protein phosphatase-1 or inhibition of
glycogen synthase kinase-3. Hubbard and Cohen (46) initially
described a model in which the inactivation of protein phos-
phatase-1 was mediated by the MAP kinase pathway. How-
ever, several recent studies question this model (reviewed in
Ref. 47). Using the phosphatidylinositol 3-kinase inhibitor
wortmannin and the p70S6K inhibitor rapamycin, Shepherd et
al. (48) reported that phosphatidylinositol 3-kinase and p70S6K
are involved in stimulation of glycogen synthesis in 3T3-L1
adipocytes. Both p70S6K and protein kinase B have been shown
to phosphorylate and inactivate glycogen synthase kinase-3 in
vitro (49, 50). However, p70S6K does not inactivate glycogen
synthase kinase-3 in all cells. Studies in L6 myocytes have led
to a new model in which the activation of phosphatidylinositol
3-kinase leads to activation of PKB which phosphorylates and
inactivates glycogen synthase kinase-3 (50). Differences in
post-receptor signaling through these pathways could underly
the differences demonstrated in our system.
In summary, these studies provide strong support for the
existence of intrinsic differences in the signaling properties of
the intracellular domains of the insulin versus the IGF-1 re-
ceptors. The greater efficiency of coupling of the insulin recep-
tor to glycogen synthesis was readily demonstratable in the
system studied despite the fact that 3T3-L1 pre-adipocytes are
relatively poorly insulin responsive compared with mature adi-
pocytes. Studies of TrkC-based chimeras in differentiated
3T3-L1 adipocytes should allow further testing of the relative
metabolic signaling capacities of the insulin versus the IGF-1
receptor intracellular domains including the examination of
specialized functions such as glucose transporter translocation
and the inhibition of lipolysis. Further studies will also be
required to precisely delineate the intracellular molecules link-
ing the receptor to glycogen synthesis which are preferentially
activated by the IR versus IGF-1R.
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